G1 Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was $98.69 Mil.
During the past 12 months, G1 Therapeutics's average Total Assets Growth Rate was -13.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 22.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 69.30% per year.
During the past 9 years, G1 Therapeutics's highest 3-Year average Total Assets Growth Rate was 158.30%. The lowest was 22.80%. And the median was 95.00%.
The historical data trend for G1 Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
G1 Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
G1 Therapeutics (NAS:GTHX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jun. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
G1 Therapeutics's Asset Turnover for the quarter that ended in Jun. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
G1 Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of G1 Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine and enhance the anti-tumor activity of current therapies. Its product COSELA indicates to help protect bone marrow from the damage of chemotherapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GTHX has been successfully added to your 